Dr. Sigalit Carmel, MD, Ph.D
Founder & CEO
Dr. Carmel is an MD and holds a PhD in immunology from the Hebrew University of Jerusalem.
Dr. Carmel has served as general practitioner at the Cardiac Intensive Care Units of Sheba and Assuta Medical Centers as well as an academic lecturer at Sapir College, where she structured new academic courses focusing on biology, immunology and medical ethics.
With a strong interdisciplinary background, Dr. Carmel founded Bioimmunate Ltd., developing an unprecedented device-based therapy for Multiple Sclerosis and other autoimmune diseases, as well as for managing the post-transplantation rejection
of solid organs.
Dr. Ron Pinkus, CTO & Head of CMC
Ronny holds a PhD from the Weizmann Institute of Science and an MBA from the Polytechnic Institute of New York; he brings with him over 27 years of experience in pharmaceuticals and biotechnology and in manufacturing and CMC Consulting over 10 years’ experience for various top biotechnology leading companies. Ronny is an expert in process development, scale-up, DSP, UPS, Analytics and CMC (Chemistry, Manufacturing & Controls) of recombinant protein and synthetic polypeptides. He has significant expertise as it relates to GMP issues in pharmaceutical manufacturing for various types of products, including small molecules, recombinant proteins, glycans, pegylation, liposomes and viruses/phages for both ethical and biosimilar/generic Drugs. Prior joining Bioimmunate, Ronny held several managing positions at InterPharm, Merck Serono, Teva Pharmaceuticals Industries, InSight Biopharmaceuticals, BiomX and Moebius Medical.
Mr. Eitan Yanuv,
VP Business Development
Has over 15 years of experience in financial consulting and business development and investment banking. Served as chairman and chief financial officer of publicly traded overseas companies. Led public company offerings on the London Stock Exchange including Brack Capital, Tech Financials, StarCom and more. He is the CEO of the firm of founding consultancy, which he founded and serves on several boards of directors of private companies and listed on the London Stock Exchange.